Bayer/Onyx initiate new Phase III trial for Nexavar in liver cancer

Bayer and Onyx have announced the initiation of a Phase III study of Nexavar (sorafenib) as an adjuvant therapy for patients with hepatocellular carcinoma

Sunitinib and Sorafenib cause Erythrocytosis, Indicative of class effect?

Researchers report that the development of reversible erythrocytosis is a common side effect following the use of sorafenib and sunitiniband may be a class specific adverse effect with all kinase inhibitors

Sorafenib in Neurofibromatosis/Neurofibromas

The NCI are initiating a phase I trial of Sorafenib in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery

NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel  are not  effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.

Sorafenib and Bevacizumab combination therapy increases antitumor activity

Combining Sorafenib and Bevacizumab has been shown to increase antitumur activity in patients with advanced solid tumors, especially those with ovarian cancer.

Nexavar approved for hepatocellular carcinoma in China

Bayer and Onyx have announced that Nexavar has been approved for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer in China

Sorafenib shows efficacy in Phase III hepatocellular carcinoma trial

Sorafenib has been shown to be effective in patients with advanced hepatocellular carcinoma. The median survival and time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.

Phase II data shows Sorafenib to demonstrate efficacy in advanced thyroid cancer

Phase II data show sorafenib to demonstrate efficacy in patients with advanced thyroid carcinoma. The overall clinical benefit rate (partial response + stable disease) was 77% and the drug had an acceptable safety profile.

Nexavar clinical data presented at ASCO

Lung cancer – Phase II results show ‘encouraging’ results in heavily pre-treated patients. Nexavar continuation resulted in longer periods of disease control
Thyroid Cancer -Phase II results show Nexavar displayed anti-tumor activity in the majority of patients
GIST – Phase II results show that Nexavar is active and well tolerated in patients with Gleevec or Gleevec [...]

Nexavar improves survival in liver cancer by 47percent

Nexavar (sorafenib) has been shown to significantly improve overall survival by 47.3% in a phase III trial in patients with either advanced hepatocellular carcinoma or primary liver cancer